For the success of adeno-associated virus (AAV)-based gene therapies, accurate viral titration is non-negotiable. But as interest in AAVs as delivery vectors soars, so does the challenge of getting consistent, reproducible genome titers—a critical hurdle in biologics workflows where speed and standardization are paramount.
Impact of DNase Digestion on Accuracy
A recent peer-reviewed study pinpoints a surprising source of this variability: the DNase digestion, a common step used to remove contaminating DNA. “[DNase digestion]… led to a significant decrease in genome titers for several AAV serotypes,” the authors write,highlighting concerns around workflow reproducibility and data reliability.The research, published in Molecular Therapy: Methods & Clinical Development, demonstrates how different engineered AAV serotypes respond inconsistently to standard DNase treatment, significantly impacting final titer results. These findings are particularly relevant for scientists developing and optimizing cell and gene therapy platforms, where regulatory expectations for analytical precision continue to rise.
This study addresses the challenge of accurately measuring viral titers in engineered AAVs, which have enhanced transduction efficiency but exhibit lower yields when measured using traditional genome titering methods. Specifically, the authors explored the impact of DNase digestion on the stability of engineered AAV capsids that contain peptide insertions. Through a series of rigorous experiments including electron microscopy, quantitative PCR (qPCR) and digital droplet PCR (ddPCR), they found that the heat-inactivation step commonly used following DNase treatment to eliminate free-floating DNA can compromise the integrity of engineered AAV capsids.
This thermal instability leads to artificially low titer measurements. The study showed that for thermally sensitive variants like AAV2-7m8, AAV9-7m8, and PHP.eB, using an alternative genome titering approach resulted in significantly higher and more reliable titers. This work underscores the importance of adapting your titering methods to account for the lower thermal stability of engineered AAV variants, particularly when comparing their performance with parental serotypes.
DNase-Free Solution for Reliable AAV Titering
What if you could bypass this source of variability entirely? This is precisely why the TruTiter™ Reagent System was developed. The DNase-free technique simplifies sample preparation and provides qPCR-ready AAV genomes in less than an hour, helping researchers accelerate their timelines. This approach is based upon a novel membrane impermeable molecule that binds to any exposed nucleic acids, preventing downstream amplification. Because this protocol is enzyme-free, there are no harsh heat inactivation steps necessary, ensuring AAV samples, particularly sensitive engineered capsid variants, will not undergo artificial degradation, resulting in more accurate genome titering measurements.
Built for the demands of biologics and therapeutic development, TruTiter is compatible with a broad range of AAV serotypes, making it adaptable to diverse applications. This flexibility helps labs save time and improve data reliability across large sample sets and with evolving constructs. By reducing variability and simplifying the workflow, you can get more reproducible data, enabling faster decision-making and greater confidence in the accuracy of your AAV titers.
Solutions for Every Step
Want to accelerate your gene therapy development workflow? Explore our Cell and Gene Therapy Solutions and Resources to learn more.
Latest posts by Darcia Schweitzer (see all)
- Solving the AAV Titer Challenge: A New Approach to Gene Therapy Workflows - December 10, 2025
- Cytochrome P450 Inhibition: Old Drug, New Tricks - May 5, 2022
- Firefly Luciferase Sheds Light on Development of New Malaria Treatments - April 5, 2021
